Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

Abstract Introduction Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA‐approved as front‐line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off‐protocol and post‐front‐line experience with combination TKI–IO appro...

Full description

Bibliographic Details
Main Authors: Andrew L. Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita‐Saavedra, Landon C. Brown, Chester Kao, Emily N. Kinsey, Rajan T. Gupta, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T. Campbell
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
combination
immunotherapy
metastatic renal cell carcinoma
salvage therapy
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.3812

Internet

https://doi.org/10.1002/cam4.3812

Similar Items